var docs;if (!docs) docs =[]; docs["109"]={"10900":"<p><b>Title</b> Methoxyflurane / Aminoglycosides</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction likely applies only to systemic aminoglycosides.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> It may be advisable to use anesthetics such as isoflurane or halothane, which are not nephrotoxic in patients being treated with an aminoglycoside. If methoxyflurane is used, it may be best to avoid aminoglycosides for at least 3 days following anesthesia.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> The nephrotoxic potential of methoxyflurane<sup>1,2</sup> is enhanced by aminoglycoside antibiotics in experimental animals.<sup>3</sup> Case reports provide suggestive but not conclusive evidence for a similar interaction in humans.<sup>4,5,6</sup> In one report, a 50-year-old male who underwent a 9-hour operative procedure with methoxyflurane anesthesia.<sup>5</sup> Postoperative laboratories were indicative of mild methoxyflurane nephrotoxicity. On the third postoperative day, gentamicin was started. Subsequently, the patient developed vasopressin-resistant diabetes insipidus, marked dehydration, and renal failure with creatinine clearance falling to 36 mL/min by the 12th postoperative day. Moderate renal dysfunction persisted in this patient.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mazze RI, Shue GL, Jackson SH. Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation. <i>JAMA</i>. 1971;216(2):278-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107910\">[PubMed 5107910]</a></p>\n<p>2. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. <i>JAMA</i>. 1973;225(13):1611-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740737\">[PubMed 4740737]</a></p>\n<p>3. Barr GA, Mazze RI, Cousins MJ, Kosek JC. An animal model for combined methoxyflurane and gentamicin nephrotoxicity. <i>Br J Anaesth</i>. 1973;45(4):306-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4705480\">[PubMed 4705480]</a></p>\n<p>4. Hollenberg NK, McDonald FD, Cotran R, et al. Irreversible acute oliguric renal failure. A complication of methoxyflurane anesthesia. <i>N Engl J Med</i>. 1972;286(16):877-879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5061073\">[PubMed 5061073]</a></p>\n<p>5. Mazze RI, Cousins MJ. Combined nephrotoxicity of gentamicin and methoxyflurane anaesthesia in man. A case report. <i>Br J Anaesth</i>. 1973;45(4):394-398. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4705491\">[PubMed 4705491]</a></p>\n<p>6. Churchill D, Knaack J, Chirito E, et al. Persisting renal insufficiency after methoxyflurane anesthesia. Report of two cases and review of literature. <i>Am J Med</i>. 1974;56(4):575-582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4818422\">[PubMed 4818422]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10901":"<p><b>Title</b> Methoxyflurane / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid methoxyflurane anesthesia in patients who are receiving barbiturates. If methoxyflurane is used, barbiturates should be discontinued at least seven days in advance.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> The nephrotoxicity of methoxyflurane metabolites has been demonstrated in man, as has the stimulation of hepatic microsomal enzymes by barbiturates. Animal studies demonstrate that pretreatment with barbiturates increases the incidence of methoxyflurane nephrotoxicity by increasing production of toxic metabolites (inorganic fluoride and oxalate).<sup>1,2,3</sup> Cases supporting the occurrence of this interaction in humans have been reported.<sup>4,5</sup> Although the documentation for this interaction in humans is sparse, the availability of alternative agents makes administration of this combination unnecessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cook TL, Beppu WJ, Hitt BA, Kosek JC, Mazze RI. A comparison of renal effects and metabolism of sevoflurane and methoxyflurane in enzyme-induced rats. <i>Anesth Analg</i>. 1975;54(6):829-835. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1239223\">[PubMed 1239223]</a></p>\n<p>2. Mazze RI, Hitt BA, Cousins MJ. Effect of enzyme induction with phenobarbital on the in vivo and in vitro defluorination of isoflurane and methoxyflurane. <i>J Pharmacol Exp Ther</i>. 1974;190(3):523-529. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4413045\">[PubMed 4413045]</a></p>\n<p>3. Cousins MJ, Mazze RI, Kosek JC, Hitt BA, Love FV. The etiology of methoxyflurane nephrotoxicity. <i>J Pharmacol Exp Ther</i>. 1974;190(3):530-541. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4416261\">[PubMed 4416261]</a></p>\n<p>4. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. <i>JAMA</i>. 1973;225(13):1611-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740737\">[PubMed 4740737]</a></p>\n<p>5. Churchill D, Yacoub JM, Siu KP, Symes A, Gault MH. Toxic nephropathy after low-dose methoxyflurane anesthesia: drug interaction with secobarbital? <i>Can Med Assoc J</i>. 1976;114(4):326-328, 333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1253070\">[PubMed 1253070]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10902":"<p><b>Title</b> Methoxyflurane / Colistimethate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Colistimethate may enhance the nephrotoxic effect of Methoxyflurane. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If possible, avoid this drug combination. Monitor renal function closely if the combination cannot be avoided.</p> \n<p><b>Discussion</b> Methoxyflurane use has been associated with a risk for nephrotoxicity,<sup>1,2,3,4</sup> and according to methoxyflurane labeling, that risk may increase with concurrent use of nephrotoxic antibiotics such as tetracycline, aminoglycosides, colistin, polymyxin B, or amphotericin B.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mazze RI, Shue GL, Jackson SH. Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation. <i>JAMA</i>. 1971;216(2):278-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107910\">[PubMed 5107910]</a></p>\n<p>2. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. <i>JAMA</i>. 1973;225(13):1611-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740737\">[PubMed 4740737]</a></p>\n<p>3. Penthrox (methoxyflurane) [summary of product characteristics]. Springvale, Victoria, Australia: Medical Developments International Ltd.; July 2015.</p>\n<p>4. Penthrox (methoxyflurane) [summary of product characteristics]. Hertfordshire, United Kingdom: Medical Developments UK Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10903":"<p><b>Title</b> Polymyxin B / Methoxyflurane</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Methoxyflurane may enhance the nephrotoxic effect of Polymyxin B. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If possible, avoid this drug combination. Monitor renal function closely if the combination cannot be avoided.</p> \n<p><b>Discussion</b> Methoxyflurane use has been associated with a risk for nephrotoxicity,<sup>1,2,3,4</sup> and according to methoxyflurane labeling, that risk may increase with concurrent use of nephrotoxic antibiotics such as tetracycline, aminoglycosides, colistin, polymyxin B, or amphotericin B.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mazze RI, Shue GL, Jackson SH. Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation. <i>JAMA</i>. 1971;216(2):278-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107910\">[PubMed 5107910]</a></p>\n<p>2. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. <i>JAMA</i>. 1973;225(13):1611-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740737\">[PubMed 4740737]</a></p>\n<p>3. Penthrox (methoxyflurane) [summary of product characteristics]. Springvale, Victoria, Australia: Medical Developments International Ltd.; July 2015.</p>\n<p>4. Penthrox (methoxyflurane) [summary of product characteristics]. Hertfordshire, United Kingdom: Medical Developments UK Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10904":"<p><b>Title</b> Amphotericin B / Methoxyflurane</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Methoxyflurane may enhance the nephrotoxic effect of Amphotericin B. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If possible, avoid this drug combination. Monitor renal function closely if the combination cannot be avoided.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> Methoxyflurane use has been associated with a risk for nephrotoxicity,<sup>1,2,3,4</sup> and according to methoxyflurane labeling, that risk may increase with concurrent use of nephrotoxic antibiotics such as tetracycline, aminoglycosides, colistin, polymyxin B, or amphotericin B.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mazze RI, Shue GL, Jackson SH. Renal dysfunction associated with methoxyflurane anesthesia. A randomized, prospective clinical evaluation. <i>JAMA</i>. 1971;216(2):278-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107910\">[PubMed 5107910]</a></p>\n<p>2. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. <i>JAMA</i>. 1973;225(13):1611-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4740737\">[PubMed 4740737]</a></p>\n<p>3. Penthrox (methoxyflurane) [summary of product characteristics]. Springvale, Victoria, Australia: Medical Developments International Ltd.; July 2015.</p>\n<p>4. Penthrox (methoxyflurane) [summary of product characteristics]. Hertfordshire, United Kingdom: Medical Developments UK Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10905":"<p><b>Title</b> Beta-Blockers / Methoxyflurane</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methoxyflurane may enhance the hypotensive effect of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of hypotension with use of this combination and caution patients about the possible increase in risk for hypotension with use of this combination.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> The methoxyflurane labeling states that the risk for hypotension may be increased with concurrent use of beta-blockers.<sup>1</sup> Hypotension has been reported with methoxyflurane,<sup>1,2</sup> and it is a known side effect of beta-blocker treatment. The exact risk, magnitude, and clinical significance of the reported interaction are all uncertain.<br><br>The most likely mechanism of any interaction is additive hypotensive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penthrox (methoxyflurane) [summary of product characteristics]. Springvale, Victoria, Australia: Medical Developments International Ltd.; July 2015.</p>\n<p>2. Penthrox (methoxyflurane) [summary of product characteristics]. Hertfordshire, United Kingdom: Medical Developments UK Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10906":"<p><b>Title</b> Dabigatran Etexilate / Lovastatin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lovastatin may enhance the anticoagulant effect of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative HMG-CoA reductase inhibitor (statin) in patients taking dabigatran who require statin therapy. If used together, monitor patients closely for signs and symptoms of bleeding.</p> \n<p><b>Discussion</b> The odds for hospitalization due to major bleeding were statistically significantly greater among patients 66 years-of-age or older receiving dabigatran etexilate who were also treated with simvastatin or lovastatin than with another statin in a population-based, nested case-control study that included 1117 cases and 4465 matched controls (adjusted OR=1.46; 95% CI= 1.17 to 1.82).<sup>1</sup><br><br>The mechanism of this reported interaction is uncertain. The authors of this study suggest this interaction could be due to simvastatin and lovastatin inhibition of the p-glycoprotein efflux of dabigatran, increasing the effect of dabigatran.<sup>1</sup> However, the evidence in support of a p-glycoprotein inhibiting effect of simvastatin and lovastatin is almost exclusively limited to in vitro and animal data. The limited in vivo data with known p-glycoprotein substrates (including digoxin, aliskiren, talinolol, and sitaglipitin) has shown no effect or only a minimal effect of simvastatin or lovastatin on the concentrations of these p-glycoprotein substrates,<sup>2,3,4,5,6</sup> suggesting these statins exert no clinically relevant p-glycoprotein inhibition. In contrast, one study does report a 63% increase in the AUC of the p-glycoprotein substrate verapamil with concomitant administration of lovastatin, although the relative contribution of CYP3A4, p-glycoprotein, or another mechanism is unclear.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Macdonald EM, Yao Z, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>CMAJ</i>. 2016 Nov (Epub ahead of print).</p>\n<p>2. Cerra M, Luo WL, Li SX, et al. The effects of simvastatin on the pharmacokinectics of sitagliptin. <i>J Popul Ther Clin Pharmacol</i>. 2012;19(3):e356-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23077137\">[PubMed 23077137]</a></p>\n<p>3. Bernsdorf A, Giessmann T, Modess C, et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. <i>Br J Clin Pharmacol</i>. 2006;61(4):440-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16542205\">[PubMed 16542205]</a></p>\n<p>4. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. <i>Int J Clin Pharmacol Ther</i>. 2005;43(11):527-535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16300168\">[PubMed 16300168]</a></p>\n<p>5. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>6. Altoprev (lovastatin) extended-release tablets [prescribing information]. Ft. Lauderdale, FL: Watson Laboratories; April 2014.</p>\n<p>7. Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. <i>Eur J Clin Pharmacol</i>. 2010;66(3):285-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20012601\">[PubMed 20012601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10907":"<p><b>Title</b> Dabigatran Etexilate / Simvastatin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Simvastatin may enhance the anticoagulant effect of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative HMG-CoA reductase inhibitor (statin) in patients taking dabigatran who require statin therapy. If used together, monitor patients closely for signs and symptoms of bleeding.</p> \n<p><b>Discussion</b> The odds for hospitalization due to major bleeding were statistically significantly greater among patients 66 years-of-age or older receiving dabigatran etexilate who were also treated with simvastatin or lovastatin than with another statin in a population-based, nested case-control study that included 1117 cases and 4465 matched controls (adjusted OR=1.46; 95% CI= 1.17 to 1.82).<sup>1</sup><br><br>The mechanism of this reported interaction is uncertain. The authors of this study suggest this interaction could be due to simvastatin and lovastatin inhibition of the p-glycoprotein efflux of dabigatran, increasing the effect of dabigatran.<sup>1</sup> However, the evidence in support of a p-glycoprotein inhibiting effect of simvastatin and lovastatin is almost exclusively limited to in vitro and animal data. The limited in vivo data with known p-glycoprotein substrates (including digoxin, aliskiren, talinolol, and sitaglipitin) has shown no effect or only a minimal effect of simvastatin or lovastatin on the concentrations of these p-glycoprotein substrates,<sup>2,3,4,5,6</sup> suggesting these statins exert no clinically relevant p-glycoprotein inhibition. In contrast, one study does report a 63% increase in the AUC of the p-glycoprotein substrate verapamil with concomitant administration of lovastatin, although the relative contribution of CYP3A4, p-glycoprotein, or another mechanism is unclear.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Macdonald EM, Yao Z, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>CMAJ</i>. 2016 Nov (Epub ahead of print).</p>\n<p>2. Cerra M, Luo WL, Li SX, et al. The effects of simvastatin on the pharmacokinectics of sitagliptin. <i>J Popul Ther Clin Pharmacol</i>. 2012;19(3):e356-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23077137\">[PubMed 23077137]</a></p>\n<p>3. Bernsdorf A, Giessmann T, Modess C, et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. <i>Br J Clin Pharmacol</i>. 2006;61(4):440-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16542205\">[PubMed 16542205]</a></p>\n<p>4. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. <i>Int J Clin Pharmacol Ther</i>. 2005;43(11):527-535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16300168\">[PubMed 16300168]</a></p>\n<p>5. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>6. Altoprev (lovastatin) extended-release tablets [prescribing information]. Ft. Lauderdale, FL: Watson Laboratories; April 2014.</p>\n<p>7. Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. <i>Eur J Clin Pharmacol</i>. 2010;66(3):285-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20012601\">[PubMed 20012601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10923":"<p><b>Title</b> Ledipasvir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and carbamazepine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Carbamazepine is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1</sup> Data evaluating carbamazepine as a P-gp inducer are mixed, with some studies concluding that carbamazepine may induce P-gp,<sup>2,3</sup> while others suggest that carbamazepine does not induce P-gp.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. <i>Br J Clin Pharmacol</i>. 2012;73(3):478-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21950458\">[PubMed 21950458]</a></p>\n<p>3. Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. <i>Ther Drug Monit</i>. 2009;31(6):764-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19855315\">[PubMed 19855315]</a></p>\n<p>4. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. <i>Clin Pharmacol Ther</i>. 2008;84(1):52-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17971810\">[PubMed 17971810]</a></p>\n<p>5. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clin Pharmacol Ther</i>. 2004;76(3):192-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371980\">[PubMed 15371980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10924":"<p><b>Title</b> Ledipasvir / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and phenobarbital.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Phenobarbital is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and potential induction of P-gp is supported by some in vitro data.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>3. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>4. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10925":"<p><b>Title</b> Ledipasvir / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and primidone.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Phenobarbital, the active metabolite of primidone, is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and potential induction of P-gp is supported by some in vitro data.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>3. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>4. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10926":"<p><b>Title</b> Ledipasvir / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and tipranavir/ritonavir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Tipranavir/ritonavir is listed in the prescribing information as a combination of agents that potentially interacts via this mechanism.<sup>1</sup> However, while tipranavir alone may induce P-gp, when it is combined with the P-gp inhibitor ritonavir the net effect on P-gp substrates appears negligible.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. <i>Clin Pharmacol Ther</i>. 2010;87(6):735-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20147896\">[PubMed 20147896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10927":"<p><b>Title</b> Sofosbuvir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Sofosbuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of sofosbuvir and carbamazepine.</p> \n<p><b>Discussion</b> The sofosbuvir AUC was an average of 72% lower with concurrent use of the P-glycoprotein (P-gp) inducer rifampin in a study of 17 subjects who received rifampin (600 mg daily) and a single dose of sofosbuvir (400 mg).<sup>1</sup> <br><br>Sofosbuvir prescribing information recommends avoiding concomitant use with agents that induce intestinal P-gp, due to the potential for diminished sofosbuvir exposure and effects.<sup>1,2</sup> Carbamazepine is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1,2</sup> Data evaluating carbamazepine as a P-gp inducer are mixed, with some studies concluding that carbamazepine may induce P-gp,<sup>3,4</sup> while others suggest that carbamazepine does not induce P-gp.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2015.</p>\n<p>3. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. <i>Br J Clin Pharmacol</i>. 2012;73(3):478-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21950458\">[PubMed 21950458]</a></p>\n<p>4. Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. <i>Ther Drug Monit</i>. 2009;31(6):764-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19855315\">[PubMed 19855315]</a></p>\n<p>5. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. <i>Clin Pharmacol Ther</i>. 2008;84(1):52-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17971810\">[PubMed 17971810]</a></p>\n<p>6. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clin Pharmacol Ther</i>. 2004;76(3):192-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371980\">[PubMed 15371980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10928":"<p><b>Title</b> Sofosbuvir / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Sofosbuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of sofosbuvir and phenobarbital.</p> \n<p><b>Discussion</b> The sofosbuvir AUC was an average of 72% lower with concurrent use of the P-glycoprotein (P-gp) inducer rifampin in a study of 17 subjects who received rifampin (600 mg daily) and a single dose of sofosbuvir (400 mg).<sup>1</sup><br><br>Sofosbuvir prescribing information recommends avoiding concomitant use with agents that induce intestinal P-gp, due to the potential for diminished sofosbuvir exposure and effects.<sup>1,2</sup> Phenobarbital is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and potential induction of P-gp is supported by some in vitro data.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2015.</p>\n<p>3. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>4. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>5. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10929":"<p><b>Title</b> Sofosbuvir / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Sofosbuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of sofosbuvir and primidone.</p> \n<p><b>Discussion</b> The sofosbuvir AUC was an average of 72% lower with concurrent use of the P-glycoprotein (P-gp) inducer rifampin in a study of 17 subjects who received rifampin (600 mg daily) and a single dose of sofosbuvir (400 mg).<sup>1</sup><br><br>Sofosbuvir prescribing information recommends avoiding concomitant use with agents that induce intestinal P-gp, due to the potential for diminished sofosbuvir exposure and effects.<sup>1,2</sup> Phenobarbital, the active metabolite of primidone, is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and potential induction of P-gp is supported by some in vitro data.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2015.</p>\n<p>3. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>4. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>5. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10930":"<p><b>Title</b> Sofosbuvir / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Sofosbuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of sofosbuvir and tipranavir/ritonavir.</p> \n<p><b>Discussion</b> The sofosbuvir AUC was an average of 72% lower with concurrent use of the P-glycoprotein (P-gp) inducer rifampin in a study of 17 subjects who received rifampin (600 mg daily) and a single dose of sofosbuvir (400 mg).<sup>1</sup> <br><br>Sofosbuvir prescribing information recommends avoiding concomitant use with agents that induce intestinal P-gp, due to the potential for diminished sofosbuvir exposure and effects.<sup>1,2</sup> Tipranavir/ritonavir is listed in the prescribing information as a combination of agents that potentially interacts via this mechanism.<sup>1,2</sup> However, while tipranavir alone may induce P-gp, when it is combined with the P-gp inhibitor ritonavir the net effect on P-gp substrates appears negligible.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2015.</p>\n<p>3. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. <i>Clin Pharmacol Ther</i>. 2010;87(6):735-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20147896\">[PubMed 20147896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10931":"<p><b>Title</b> Afatinib / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of carbamazepine. The dose should then be reduced back to the original afatinib dose 2-3 days after discontinuation of carbamazepine. The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.</p> \n<p><b>Discussion</b> In a clinical study summarized in afatinib US prescribing information, coadministration of rifampin (600 mg daily for 7 days) decreased the maximum concentration and AUC of afatinib by 22% and 34%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of P-glycoprotein (P-gp)-mediated efflux of afatinib.<br><br>The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib, with subsequent reduction back to the original afatinib dose 2-3 days after discontinuation of the P-gp inducer.<sup>1</sup> The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.<sup>2</sup><br><br>Carbamazepine is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1,2</sup> Data evaluating carbamazepine as a P-gp inducer are mixed, with some studies concluding that carbamazepine may induce P-gp,<sup>3,4</sup> while others suggest that carbamazepine does not induce P-gp.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [Prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [Product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. <i>Br J Clin Pharmacol</i>. 2012;73(3):478-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21950458\">[PubMed 21950458]</a></p>\n<p>4. Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. <i>Ther Drug Monit</i>. 2009;31(6):764-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19855315\">[PubMed 19855315]</a></p>\n<p>5. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. <i>Clin Pharmacol Ther</i>. 2008;84(1):52-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17971810\">[PubMed 17971810]</a></p>\n<p>6. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clin Pharmacol Ther</i>. 2004;76(3):192-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371980\">[PubMed 15371980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10932":"<p><b>Title</b> Afatinib / PHENobarbital</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of phenobarbital. The dose should then be reduced back to the original afatinib dose 2-3 days after discontinuation of phenobarbital. The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.</p> \n<p><b>Discussion</b> In a clinical study summarized in afatinib US prescribing information, coadministration of rifampin (600 mg daily for 7 days) decreased the maximum concentration and AUC of afatinib by 22% and 34%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of P-glycoprotein (P-gp)-mediated efflux of afatinib.<br><br>The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib, with subsequent reduction back to the original afatinib dose 2-3 days after discontinuation of the P-gp inducer.<sup>1</sup> The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.<sup>2</sup><br><br>Phenobarbital is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and induction of P-gp is supported by some in vitro data.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [Prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [Product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>4. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>5. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10933":"<p><b>Title</b> Afatinib / Primidone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of primidone. The dose should then be reduced back to the original afatinib dose 2-3 days after discontinuation of primidone. The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.</p> \n<p><b>Discussion</b> In a clinical study summarized in afatinib US prescribing information, coadministration of rifampin (600 mg daily for 7 days) decreased the maximum concentration and AUC of afatinib by 22% and 34%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of P-glycoprotein (P-gp)-mediated efflux of afatinib.<br><br>The US prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib, with subsequent reduction back to the original afatinib dose 2-3 days after discontinuation of the P-gp inducer.<sup>1</sup> The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.<sup>2</sup><br><br>Phenobarbital, the active metabolite of primidone, is listed in the prescribing information as an agent that potentially interacts via this mechanism despite a lack of specific P-gp inducing data in the published literature. However, phenobarbital does induce CYP-450 enzymes and induction of P-gp is supported by some in vitro data.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [Prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [Product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vivo. <i>Drug Metab Dispos</i>. 2008;36(3):604-613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094037\">[PubMed 18094037]</a></p>\n<p>4. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>Br J Pharmacol</i>. 2008;153(4):805-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18037906\">[PubMed 18037906]</a></p>\n<p>5. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. <i>Drug Metab Dispos</i>. 2006;34(10):1756-1763. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837569\">[PubMed 16837569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10934":"<p><b>Title</b> Afatinib / Tacrolimus (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may increase the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of afatinib toxicity during concomitant treatment with tacrolimus. The US prescribing information recommends to reduce the afatinib dose by 10 mg if not tolerated and to increase back to the original afatinib dose following discontinuation of tacrolimus as tolerated. The Canadian product monograph recommends avoiding concurrent use. If such a combination is needed, tacrolimus should be given simultaneously with or after the afatinib dose.</p> \n<p><b>Discussion</b> In clinical studies summarized in afatinib US prescribing information, coadministration of the P-glycoprotein (P-gp) inhibitor ritonavir (200 mg twice daily for 3 days) increased the maximum concentration and AUC of afatinib in a time-dependent manner: by 39% and 48%, respectively, when ritonavir was given 1 h before afatinib (20 mg single dose); by 4% and 19%, respectively, when ritonavir was given simultaneously with afatinib (40 mg single dose); and by 5% and 11%, respectively, when ritonavir was given 6 hours after afatinib (40 mg single dose).<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ritonavir inhibition of P-gp-mediated efflux of afatinib. Tacrolimus is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1,2</sup> Although in vitro data suggest tacrolimus may inhibit P-gp,<sup>3,4,5,6</sup> no clinical studies have been conducted to assess the effect of tacrolimus on P-gp substrates. Considering the differences in the interaction magnitude with different administration times, the Canadian product monograph recommends that if such concurrent use is required, tacrolimus should be given simultaneously with or after the dose of afatinib.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. Quezada CA, Garrido WX, Gonzalez-Oyarzun MA, et al. Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. <i>Biol Pharm Bull</i>. 2008;31(10):1911-1916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18827354\">[PubMed 18827354]</a></p>\n<p>4. Tanaka S, Hirano T, Saito T, Wakata N, Oka K. P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. <i>Biol Pharm Bull</i>. 2007;30(2):291-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17268068\">[PubMed 17268068]</a></p>\n<p>5. Parasrampuria DA, Lantz MV, Birnbaum JL, Vincetia FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. <i>J Clin Pharmacol</i>. 2002;42(3):304-311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11865967\">[PubMed 11865967]</a></p>\n<p>6. Parasrampuria DA, Lantz MV, Benet LZ. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. <i>Pharm Res</i>. 2001;18(1):39-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11336351\">[PubMed 11336351]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10935":"<p><b>Title</b> Afatinib / Saquinavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of afatinib toxicity during concomitant treatment with saquinavir. The US prescribing information recommends to reduce the afatinib dose by 10 mg if not tolerated and to increase back to the original afatinib dose following discontinuation of saquinavir as tolerated. The Canadian product monograph recommends avoiding concurrent use. If such a combination is needed, saquinavir should be given simultaneously with or after the afatinib dose.</p> \n<p><b>Discussion</b> In clinical studies summarized in afatinib US prescribing information, coadministration of the P-glycoprotein (P-gp) inhibitor ritonavir (200 mg twice daily for 3 days) increased the maximum concentration and AUC of afatinib in a time-dependent manner: by 39% and 48%, respectively, when ritonavir was given 1 h before afatinib (20 mg single dose); by 4% and 19%, respectively, when ritonavir was given simultaneously with afatinib (40 mg single dose); and by 5% and 11%, respectively, when ritonavir was given 6 hours after afatinib (40 mg single dose).<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ritonavir inhibition of P-gp-mediated efflux of afatinib. Saquinavir is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1,2</sup> Some in vitro studies suggest saquinavir may inhibit P-gp,<sup>3,4</sup> while other analyses conclude that saquinavir does not inhibit P-gp.<sup>5,6</sup> Considering the differences in the interaction magnitude with different administration times, the Canadian product monograph recommends that if such concurrent use is required, saquinavir should be given simultaneously with or after the dose of afatinib.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. <i>Biochem Pharmacol</i>. 2007;73(10):1573-1581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17328866\">[PubMed 17328866]</a></p>\n<p>4. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>. 1998;19(3):203-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9803961\">[PubMed 9803961]</a></p>\n<p>5. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. <i>Biol Pharm Bull</i>. 2000;23(12):1528-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11145192\">[PubMed 11145192]</a></p>\n<p>6. Mikus G, Schmidt L, Burhenne J, et al. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. <i>Clin Pharmacokinet</i>. 2004;43(14):1015-1024. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15530130\">[PubMed 15530130]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10936":"<p><b>Title</b> Afatinib / Nelfinavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of afatinib toxicity during concomitant treatment with nelfinavir. The US prescribing information recommends to reduce the afatinib dose by 10 mg if not tolerated and to increase back to the original afatinib dose following discontinuation of nelfinavir as tolerated. The Canadian product monograph recommends avoiding concurrent use. If such a combination is needed, nelfinavir should be given simultaneously with or after the afatinib dose.</p> \n<p><b>Discussion</b> In clinical studies summarized in afatinib US prescribing information, coadministration of the P-glycoprotein (P-gp) inhibitor ritonavir (200 mg twice daily for 3 days) increased the maximum concentration and AUC of afatinib in a time-dependent manner: by 39% and 48%, respectively, when ritonavir was given 1 h before afatinib (20 mg single dose); by 4% and 19%, respectively, when ritonavir was given simultaneously with afatinib (40 mg single dose); and by 5% and 11%, respectively, when ritonavir was given 6 hours after afatinib (40 mg single dose).<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ritonavir inhibition of P-gp-mediated efflux of afatinib. Nelfinavir is listed in the prescribing information as an agent that potentially interacts via this mechanism.<sup>1,2</sup> Although nelfinavir has been shown to inhibit P-gp in vitro,<sup>3,4</sup> clinical data suggest that nelfinavir does not significantly inhibit P-gp.<sup>5</sup> Considering the differences in the interaction magnitude with different administration times, the Canadian product monograph recommends that if such concurrent use is required, the P-gp inhibitor should be given simultaneously with or after the dose of afatinib.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilotrif (afatinib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2013.</p>\n<p>2. Giotrif (afatinib) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; August 2016.</p>\n<p>3. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. <i>Biochem Pharmacol</i>. 2007;73(10):1573-1581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17328866\">[PubMed 17328866]</a></p>\n<p>4. Beghin D, Forestier F, Noel-Hudson MS, et al. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2010;152(1):55-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20591557\">[PubMed 20591557]</a></p>\n<p>5. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. <i>Drug Metab Dispos</i>. 2012;40(3):610-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190694\">[PubMed 22190694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10937":"<p><b>Title</b> Aspirin / Felbinac</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Felbinac may enhance the adverse/toxic effect of Aspirin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased aspirin toxicities (eg, bleeding) if combined with topical felbinac.</p> \n<p><b>Discussion</b> Felbinac prescribing information states that although the topical application of felbinac results in low circulating levels of felbinac in serum (more than 20 times less than the levels recorded following oral administration), concurrent use of aspirin or other NSAIDs with felbinac may result in an increased incidence of adverse reactions.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Traxam (felbinac) gel [summary of product characteristics]. Croydon, UK: Mercury Pharmaceuticals Ltd; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10938":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Felbinac</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Felbinac may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased NSAID related toxicities if oral NSAIDs are combined with topical felbinac.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Felbinac prescribing information states that although the topical application of felbinac results in low circulating levels of felbinac in serum (more than 20 times less than the levels recorded following oral administration), concurrent use of aspirin or other NSAIDs with felbinac may result in an increased incidence of adverse reactions.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Traxam (felbinac) gel [summary of product characteristics]. Croydon, UK: Mercury Pharmaceuticals Ltd; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10939":"<p><b>Title</b> Potassium Iodate / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lithium may enhance the hypothyroid effect of Potassium Iodate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of severely decreased thyroid function during concomitant therapy with lithium and potassium iodate.</p> \n<p><b>Discussion</b> Several case reports describe apparent additive effects of lithium and potassium iodide in reducing thyroid function.<sup>1,2,3,4</sup> Additionally, a study of 10 patients receiving chronic lithium therapy showed a rise in thyroid stimulating hormone and T3 following initiation of potassium iodide (250 mg orally four times daily).<sup>5</sup> Two patients developed hypothyroidism.<br><br>Both lithium and potassium iodide can diminish thyroid function. Lithium appears to block the release of thyroid hormones from the thyroid gland, while potassium iodide interrupts the production of thyroid hormones. Caution is advised when these agents are used concomitantly.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shopsin B, Shenkman L, Blum M, Hollander CS. Iodine and lithium-induced hypothyroidism. Documentation of synergism. <i>Am J Med</i>. 1973;55(5):695-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4749208\">[PubMed 4749208]</a></p>\n<p>2. Luby ED, Schwartz D, Rosenbaum H. Lithium-carbonate-induced myxedema. <i>JAMA</i>. 1971;218(8):1298-1299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5171179\">[PubMed 5171179]</a></p>\n<p>3. Jorgensen JV, Brandrup F, Schroll M. Possible synergism between iodine and lithium carbonate. <i>JAMA</i>. 1973;223(2):192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4540138\">[PubMed 4540138]</a></p>\n<p>4. Wiener JD. Lithium carbonate-induced myxedema. <i>JAMA</i>. 1972;220(4):587. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4401588\">[PubMed 4401588]</a></p>\n<p>5. Spaulding SW, Burrow GN, Ramey JN, Donabedian RK. Effect of increased iodide intake on thyroid function in subjects on chronic lithium therapy. <i>Acta Endocrinol (Copenh)</i>. 1977;84(2):290-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576345\">[PubMed 576345]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10940":"<p><b>Title</b> Protirelin / Potassium Iodate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Potassium Iodate may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10941":"<p><b>Title</b> MiFEPRIStone / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of MiFEPRIStone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming grapefruit juice with mifepristone when possible. If patients do consume grapefruit juice while being treated with mifepristone, monitor closely for evidence of excessive mifepristone effects or toxicities. Separating administration may or may not lessen the extent of the interaction.</p> \n<p><b>Discussion</b> The labeling for both mifepristone products recommends caution with concurrent use of grapefruit juice due to the potential for grapefruit juice to inhibit mifepristone CYP3A4-mediated metabolism, possibly resulting in increased mifepristone concentrations and effects.<sup>1,2</sup><br><br>Although the clinical significance of this interaction is uncertain, the patient counseling section of the Korlym-brand labeling advises patients to not drink grapefruit juice while taking mifepristone, even though that recommendation is not consistent with the grapefruit juice-related warning in the drug interactions section of the label.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; October 2016.</p>\n<p>2. Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories, LLC; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10942":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Dihydrocodeine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dihydrocodeine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution when using dihydrocodeine together with a monoamine oxidase (MAO) inhibitor or within 2 weeks of stopping an MAO inhibitor. If used together monitor closely for evidence of serotonin syndrome or related adverse effects.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Labeling for dihydrocodeine products recommend caution if used with an MAO inhibitor.<sup>1,2</sup> Although specific data with dihydrocodeine is lacking, this warning appears to be related to similar concerns with other opioids. The US Food and Drug Administration issued a general warning about the potential for opioids to cause serotonergic toxicity when used with serotonin-modulating drugs, such as MAO inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DHC Continus (dihydrocodeine) [summary of product characteristics]. Cambridge, United Kingdom: Napp Pharmaceuticals Limited; July 2016.</p>\n<p>2. Dihydrocodeine [summary of product characteristics]. Devon, United Kingdom: Actavis UK Ltd; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10943":"<p><b>Title</b> Anticoagulants / Telavancin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Telavancin may diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use telavancin cautiously in patients receiving anticoagulants where the use of the aPTT, PT, INR, or ACT are used to monitor anticoagulant safety or efficacy. The anticoagulation tests may be falsely elevated during telavancin use. The effect of telavancin on anticoagulation tests appears to last at least 18 hours. To minimize this drug-lab interaction, collect anticoagulation tests just prior to a patient's next dose (approximately 24 hours after the last telavancin dose).</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Apixaban, Argatroban, Betrixaban, Bivalirudin, Dabigatran Etexilate, Danaparoid, Desirudin, Edoxaban, Heparin, Phenindione, Rivaroxaban, Warfarin<br><b>Exceptions</b> Antithrombin, Bemiparin, Dalteparin, Enoxaparin, Fondaparinux, Nadroparin, Protein C Concentrate (Human), Tinzaparin</p>\n</div> \n<p><b>Discussion</b> The telavancin prescribing information states that although telavancin does not interfere with coagulation, it does interfere with certain tests used to monitor coagulation.<sup>1</sup> Telavancin can bind to artificial phospholipids found in coagulation reagents, reducing the in vitro clotting process and resulting in artificially prolonged clotting times.<sup>1,2,3</sup> No effect of telavancin was seen in non-phospholipid dependent assays such as chromogenic anti-factor Xa assay, functional factor X activity assay, fibrinogen, thrombin time, and D-dimer testing.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vibativ (telavancin) [prescribing information]. South San Francisco, CA: Theravance Biopharma US Inc; May 2016.</p>\n<p>2. Gosselin R, Dager W, Roberts A, et al. Effect of telavancin (Vibativ) on routine coagulation test results. <i>Am J Clin Pathol</i>. 2011;136(6):848-854. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22095369\">[PubMed 22095369]</a></p>\n<p>3. Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. <i>Int J Clin Pract</i>. 2011;65(7):784-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21564449\">[PubMed 21564449]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10944":"<p><b>Title</b> Anticoagulants / MiFEPRIStone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this potential interaction differs if mifepristone is being used for the termination of intrauterine pregnancy versus if mifepristone is being used for the treatment of hyperglycemia in patients with Cushing syndrome.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> MiFEPRIStone may enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of anticoagulants and mifepristone is contraindicated when mifepristone is being used for the termination of intrauterine pregnancy. When mifepristone is being used to treat hyperglycemia associated with Cushing syndrome, anticoagulants should be used with caution and patients should be monitored for signs and symptoms of bleeding.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Mifepristone prescribing information states that when mifepristone is being used for the termination of intrauterine pregnancy, concomitant use of anticoagulants is contraindicated.<sup>1</sup> Since uterine bleeding occurs in almost all patients during a medical abortion, the use of anticoagulants along with mifepristone may significantly worsen bleeding related complications.<sup>1</sup><br><br>Mifepristone prescribing information states that when mifepristone is being used to treat hyperglycemia associated with Cushing syndrome, concomitant use of anticoagulants should be done with caution.<sup>2</sup> Because mifepristone is a progesterone receptor antagonist, it promotes unopposed endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories LLC; March 2016. </p>\n<p>2. Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10945":"<p><b>Title</b> Dabigatran Etexilate / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of an excessive clinical response to dabigatran (eg, bruising, bleeding) if this combination is used. Consider alternative anticoagulation options when possible, and note that options such as enoxaparin or INR-guided warfarin may be preferred due to the potential for cobicistat to inhibit the CYP3A4-mediated metabolism and/or the P-glycoprotein (P-gp)-mediated transport of the other direct-acting oral anticoagulants. The dabigatran U.S. prescribing information does not specifically recommend dose reductions or contraindications with P-gp inhibitors for patients with normal renal function, although it does recommend that concurrent use of any P-gp inhibitor with dabigatran should be avoided in patients with severe renal dysfunction (CrCl 15-30 mL/min).</p> \n<p><b>Discussion</b> Simultaneous administration of dabigatran and cobicistat resulted in an average 2.3-fold increase in dabigatran AUC with a concomitant 51% increase in thrombin time (TT) after 24 hours in a study of 16 healthy HIV-negative volunteers who received a single dose of dabigatran 150 mg together with cobicistat 150 mg/day (for 3 weeks).<sup>1</sup> Generally similar results were obtained after 2 weeks of cobicistat when the dose of dabigatran was administered 2 hours prior to the cobicistat dose, suggesting that dose separation was not an effective means of diminishing the interaction (2.1-fold increase in dabigatran AUC and 46% increase in TT after 24 hours).<br><br>The mechanism of this interaction appears to be via P-glycoprotein (P-gp), as dabigatran is a substrate and cobicistat is a possible inhibitor of P-gp. According to data presented in the dabigatran prescribing information, concurrent use with other P-gp inhibitors has been associated with significant increases in dabigatran AUC and maximum serum concentration.<sup>2</sup> Cobicistat is described as a P-gp inhibitor in its labeling, but a study with digoxin, which is transported by P-gp, showed only a non-statistically significant 8% increase in digoxin AUC, raising some question about cobicistat's potency as a P-gp inhibitor.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gordon LA, Kumar P, Brooks KM, et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV negative healthy volunteers. <i>Circulation</i>. 2016;134(23):1909-1911. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27920076\">[PubMed 27920076]</a></p>\n<p>2. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>3. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10946":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Ixazomib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ixazomib may decrease the serum concentration of Estrogen Derivatives (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of estrogen derivative contraceptives. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Ixazomib US prescribing information states that patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment, because ixazomib is used in combination with dexamethasone and dexamethasone may decrease hormonal contraceptive exposure.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is dexamethasone induction of CYP3A-mediated hormonal contraceptive metabolism. In clinical studies, use of dexamethasone (1.5 to 8 mg twice daily for 3 to 4 days) was associated with only minor decreases in exposure to CYP3A4 probe drugs.<sup>2,3</sup> The impact on CYP3A function of a 40 mg single weekly dose of dexamethasone, as recommended for use in combination with ixazomib, has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November 2016.</p>\n<p>2. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>3. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10947":"<p><b>Title</b> Progestins (Contraceptive) / Ixazomib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ixazomib may decrease the serum concentration of Progestins (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of contraceptive progestins. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Ixazomib US prescribing information states that patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment, because ixazomib is used in combination with dexamethasone and dexamethasone may decrease hormonal contraceptive exposure.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is dexamethasone induction of CYP3A-mediated hormonal contraceptive metabolism. In clinical studies, use of dexamethasone (1.5 to 8 mg twice daily for 3 to 4 days) was associated with only minor decreases in exposure to CYP3A4 probe drugs.<sup>2,3</sup> The impact on CYP3A function of a 40 mg single weekly dose of dexamethasone, as recommended for use in combination with ixazomib, has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November 2016.</p>\n<p>2. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>3. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10948":"<p><b>Title</b> Ciprofloxacin (Systemic) / Patiromer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral/enteral ciprofloxacin administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Patiromer may decrease the serum concentration of Ciprofloxacin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer.</p> \n<p><b>Discussion</b> In a clinical study summarized in patiromer US prescribing information, simultaneous coadministration of patiromer decreased the average maximum concentration and AUC of oral ciprofloxacin by between 25% and 50%, while administration of patiromer and oral ciprofloxacin 3 hours apart had no impact on ciprofloxacin exposure.<sup>1</sup> The suspected primary mechanism of this interaction is patiromer binding to ciprofloxacin in the gastrointestinal tract and diminishing its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Veltassa (patiromer) [prescribing information]. Redwood City, CA: Relypsa Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10949":"<p><b>Title</b> Levothyroxine / Patiromer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral/enteral levothyroxine administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Patiromer may decrease the serum concentration of Levothyroxine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral levothyroxine at least 3 hours before or 3 hours after patiromer.</p> \n<p><b>Discussion</b> In a clinical study summarized in patiromer US prescribing information, simultaneous coadministration of patiromer decreased the average maximum concentration and AUC of oral levothyroxine by 25% or less, while administration of patiromer and oral levothyroxine 3 hours apart had no impact on levothyroxine exposure.<sup>1</sup> The suspected primary mechanism of this interaction is patiromer binding to levothyroxine in the gastrointestinal tract and diminishing its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Veltassa (patiromer) [prescribing information]. Redwood City, CA: Relypsa Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10950":"<p><b>Title</b> MetFORMIN / Patiromer</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Patiromer may decrease the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer metformin at least 3 hours before or 3 hours after patiromer.</p> \n<p><b>Discussion</b> In a clinical study summarized in patiromer US prescribing information, simultaneous coadministration of patiromer decreased the maximum concentration and AUC of metformin by between approximately 20% and 50%, while administration of patiromer and metformin 3 hours apart had no impact on metformin exposure.<sup>1</sup> The suspected primary mechanism of this interaction is patiromer binding to metformin in the gastrointestinal tract and diminishing its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Veltassa (patiromer) [prescribing information]. Redwood City, CA: Relypsa Inc; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10951":"<p><b>Title</b> Alpha-/Beta-Agonists / CloZAPine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CloZAPine may diminish the therapeutic effect of Alpha-/Beta-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased blood pressure elevating effects of alpha-/beta-agonists in patients taking clozapine. Increased doses of alpha-/beta-agonists may be required. The use of clozapine and epinephrine may cause paradoxical hypotension. Vasopressin may be a preferable alternative to increase blood pressure in patients taking clozapine.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Systemic), Metaraminol, Norepinephrine<br><b>Exceptions</b> EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), Isometheptene, Levonordefrin, Pseudoephedrine</p>\n</div> \n<p><b>Discussion</b> A case report describes a 48-year-old man on clozapine (200 mg every morning and 500 mg every evening) who presented for a biopsy of a right-sided lung mass under general anesthesia.<sup>1</sup> Intraoperatively he became hypotensive (mean arterial pressure [MAP] 40 mm Hg) and administration of fluids, ephedrine boluses (50 mg total), phenylephrine boluses (500 mcg total), and a continuous intravenous infusion of phenylephrine (1.5 mcg/kg/min) only increased his MAP to 48 mm Hg. Administration of epinephrine boluses (5 mcg to 10 mcg) had the paradoxical effect of decreasing his MAP by 5 mm Hg. A bolus of low-dose vasopressin (1 unit) was given and resulted in an immediate increase in his MAP to 78 mm Hg. Additional boluses of vasopressin (5 units total) were administered to maintain his MAP above 65 mm Hg throughout the remainder of the procedure.<sup>1</sup> Another case report describes a 54-year-old man on clozapine therapy who presented with a subarachnoid hemorrhage from an aneurysm.<sup>2</sup> After an angiogram to coil the aneurysm and balloon angioplasty for vasospastic arteries he was transferred to the neurocritical ICU with a goal to maintain his MAP greater than 110 mm Hg.<sup>2</sup> Continuous infusions of phenylephrine (0.4 mcg/kg/min) and norepinephrine (0.5 mcg/kg/min) failed to maintain his MAP goals. The addition of dobutamine (7.5 mcg/kg/min) increased his MAP to 120 mm Hg, but also increased his heart rate to 120 beats per minute (bpm) and had to be discontinued. The addition of epinephrine (0.15 mcg/kg/min) further decreased his MAP to approximately 95 mm Hg and increased his heart rate back to 120 bpm.<sup>2</sup> Epinephrine was discontinued and vasopressin was added (0.04 units/min) which resulted in rapid restoration of his MAP to greater than 110 mm Hg.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to alpha-1 receptor antagonism by clozapine blunting the vasoconstrictor effects of alpha-1 agonists. The paradoxical hypotensive effects seen when clozapine is combined with epinephrine are likely due to the alpha-1 receptor antagonism by clozapine which leaves the epinephrine induced beta-2 agonism unopposed, leading to smooth muscle relaxation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. John A, Yeh C, Boyd J, Greilich PE. Treatment of refractory hypotension with low-dose vasopressin in a patient receiving clozapine. <i>J Cardiothorac Vasc Anesth</i>. 2010;24(3):467-468. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19926306\">[PubMed 19926306]</a></p>\n<p>2. Leung JG, Nelson S, Hocker S. Failure of induced hypertension for symptomatic vasospasm in the setting of clozapine therapy. <i>Neurocrit Care</i>. 2015;23(3):409-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25792345\">[PubMed 25792345]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10952":"<p><b>Title</b> Phenylephrine (Systemic) / CloZAPine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CloZAPine may diminish the therapeutic effect of Phenylephrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased blood pressure elevating effects of phenylephrine in patients on clozapine therapy. Increased doses of phenylephrine may be required. Vasopressin may be a preferable alternative to increase blood pressure in patients taking clozapine.</p> \n<p><b>Discussion</b> A case report describes a 48-year-old man on clozapine (200 mg every morning and 500 mg every evening) who presented for a biopsy of a right-sided lung mass under general anesthesia.<sup>1</sup> Intraoperatively he became hypotensive (mean arterial pressure [MAP] 40 mm Hg) and administration of fluids, ephedrine boluses (50 mg total), phenylephrine boluses (500 mcg total), and a continuous intravenous infusion of phenylephrine (1.5 mcg/kg/min) only increased his MAP to 48 mm Hg. Administration of epinephrine boluses (5 mcg to 10 mcg) had the paradoxical effect of decreasing his MAP by 5 mm Hg. A bolus of low-dose vasopressin (1 unit) was given and resulted in an immediate increase in his MAP to 78 mm Hg. Additional boluses of vasopressin (5 units total) were administered to maintain his MAP above 65 mm Hg throughout the remainder of the procedure.<sup>1</sup> Another case report describes a 54-year-old man on clozapine therapy who presented with a subarachnoid hemorrhage from an aneurysm.<sup>2</sup> After an angiogram to coil the aneurysm and balloon angioplasty performed for vasospastic arteries he was transferred to the neurocritical ICU with a goal to maintain his MAP greater than 110 mm Hg.<sup>2</sup> Continuous infusions of phenylephrine (0.4 mcg/kg/min) and norepinephrine (0.5 mcg/kg/min) failed to maintain his MAP goals. The addition of dobutamine (7.5 mcg/kg/min) increased his MAP to 120 mm Hg, but also increased his heart rate to 120 beats per minute (bpm) and had to be discontinued. The addition of epinephrine (0.15 mcg/kg/min) further decreased his MAP to approximately 95 mm Hg and increased his heart rate back to 120 bpm.<sup>2</sup> Epinephrine was discontinued and vasopressin was added (0.04 units/min) which resulted in rapid restoration of his MAP greater than 110 mm Hg.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but is likely due to alpha-1 receptor antagonism by clozapine blunting the vasoconstrictor effects of alpha-1 agonists. The paradoxical hypotensive effects seen when clozapine was combined with epinephrine are likely due to the alpha-1 receptor antagonism by clozapine which leaves the epinephrine induced beta-2 agonism unopposed, leading to smooth muscle relaxation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. John A, Yeh C, Boyd J, Greilich PE. Treatment of refractory hypotension with low-dose vasopressin in a patient receiving clozapine. <i>J Cardiothorac Vasc Anesth</i>. 2010;24(3):467-468. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19926306\">[PubMed 19926306]</a></p>\n<p>2. Leung JG, Nelson S, Hocker S. Failure of induced hypertension for symptomatic vasospasm in the setting of clozapine therapy. <i>Neurocrit Care</i>. 2015;23(3):409-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25792345\">[PubMed 25792345]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10961":"<p><b>Title</b> ARIPiprazole / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Double the dose of oral aripiprazole when initiating concomitant therapy with a strong CYP3A4 inducer, and closely monitor clinical response to guide further dose adjustment. Reduce the oral aripiprazole adult dose to 10-15 mg/day when the strong CYP3A4 inducer is discontinued. In patients receiving extended-release injectable aripiprazole, avoid use of strong CYP3A4 inducing drugs for greater than 14 days.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a small study of schizophrenic patients (n=9, 6 of whom completed study), aripiprazole 30 mg/day was administered initially as monotherapy for 14 days, then concomitantly with carbamazepine 200 mg/day, followed by an upward titration of the carbamazepine dose over 4-6 weeks to achieve therapeutic levels (8-12 mg/L). Patients achieving therapeutic levels were receiving carbamazepine doses ranging from 500-1600 mg/day. Compared to monotherapy, concurrent carbamazepine was associated with substantial decreases in aripiprazole Cmin (74% to 78%), Cmax (66%), and AUC (71%), respectively. Concentrations of the active metabolite of aripiprazole (dehydroaripiprazole) were also significantly decreased, with a 68% decrease in Cmax, a 69% decrease in AUC, and a 72% to 74% decrease in Cmin.<sup>1</sup> Similarly, carbamazepine (400 mg/day for 1 week) decreased aripiprazole and dehydroaripiprazole plasma concentrations by 64% and 68%, respectively, in 18 Japanese schizophrenic patients who had been receiving 12 or 24 mg/day of aripiprazole for 3 to 5 weeks.<sup>2</sup> A study evaluating blood samples evaluated for routine aripiprazole therapeutic drug monitoring described one patient treated with aripiprazole and carbamazepine concurrently had a serum concentration/dose (CD) ratio that was 88% lower than that of patients treated with aripiprazole only,<sup>3</sup> and a similar study concluded that the aripiprazole CD ratio was 60% lower in 3 patients receiving CYP3A4-inducing anticonvulsants.<sup>4</sup> In another pharmacokinetic study, the weak CYP3A4 inducer, armodafanil (250 mg daily for 30 days) decreased aripiprazole (15 mg single dose) AUC 34% and decreased the dehydroaripiprazole AUC 32%.<sup>5</sup><br><br>The suspected primary mechanism of this interaction is induction of CYP3A4-mediated metabolism of aripiprazole and dehydroaripiprazole. Product labeling for oral and injectable aripiprazole products give specific recommendations for adjusting doses and limiting the duration of concomitant therapy with CYP3A4 inducers.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Citrome L, Macher Jean-Paul, Salazar D, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. <i>J Clin Psychopharm</i>. 2007;27(3):279-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17502775\">[PubMed 17502775]</a></p>\n<p>2. Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. <i>Ther Drug Monit</i>. 2009;31(5):575-578. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19701114\">[PubMed 19701114]</a></p>\n<p>3. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. <i>Pharmacopsychiatry</i>. 2007;40(3):107-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17541885\">[PubMed 17541885]</a></p>\n<p>4. Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. <i>Ther Drug Monit</i>. 2009;31(2):233-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142178\">[PubMed 19142178]</a></p>\n<p>5. Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P Jr. Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and aripiprazole in healthy adults. <i>Pharmacopsychiatry</i>. 2015;48(4-5):170-175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26181194\">[PubMed 26181194]</a></p>\n<p>6. Abilify (aripiprazole) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2011.</p>\n<p>7. Abilify Maintena (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10962":"<p><b>Title</b> ARIPiprazole / Armodafinil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Armodafinil may decrease the serum concentration of ARIPiprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased aripiprazole effects when combined with armodafinil.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, armodafinil (titrated to 250 mg/day over 49 days) decreased the aripiprazole (15 mg single dose given on day 34) AUC 34% and decreased the AUC of dehydro-aripiprazole, an equipotent metabolite, by 32%.<sup>1</sup><br><br>The mechanism of this interaction is likely due to armodafinil induction of CYP3A4, an enzyme responsible for aripiprazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P Jr. Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and aripiprazole in healthy adults. <i>Pharmacopsychiatry</i>. 2015;48(4-5):170-175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26181194\">[PubMed 26181194]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10963":"<p><b>Title</b> Riociguat / Crisaborole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Crisaborole may enhance the hypotensive effect of Riociguat. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with nonselective phosphodiesterase inhibitors or phosphodiesterase type 5 inhibitors is contraindicated due to the risk of hypotension. While other phosphodiesterase inhibitors, such as crisaborolel, are not specifically contraindicated with riociguat, concomitant use should be undertaken with caution and patients should be monitored for the development of hypotension.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with pulmonary arterial hypertension who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1 to 2.5 mg 3 times/day together with sildenafil (20 mg 3 times/day) one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination. No clinical studies have been conducted with riociguat and other types of phosphodiesterase inhibitors so the combined effect on blood pressure is unknown. Although crisaborole is applied topically, after application of crisaborole (6 grams to 30 grams per application) twice daily for 8 days in 33 pediatric patients, plasma crisaborole concentrations were detectable in all subjects.<sup>2</sup> <br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cyclic nucleotides that result in vasodilation such as cGMP or cAMP, resulting in possible additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p>2. Eucrisa (crisaborole) [prescribing information]. Palo Alto, CA: Anacor Pharmaceuticals Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10964":"<p><b>Title</b> Diuretics / Diacerein</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diacerein may enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of excessive diuretic response, such as dehydration or hypokalemia, when using a diuretic together with diacerein.</p>\n<div>\n <p><b>Diuretics Interacting Members</b> AcetaZOLAMIDE, AMILoride, Bendroflumethiazide, Bumetanide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, Dichlorphenamide, Eplerenone, Ethacrynic Acid, Furosemide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Isosorbide Solution (Diuretic), Mannitol (Systemic), MethazolAMIDE, Methyclothiazide, MetOLazone, Spironolactone, Torsemide, Triamterene, Xipamide</p>\n</div> \n<p><b>Discussion</b> The diacerein labeling states that concurrent use with diuretics may increase the risk for dehydration and hypokalemia, an effect that appears to be secondary to a potential increase in the actions of diuretics.<sup>1</sup> Specific data regarding this labeled interaction are not available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diacerein [prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802489. Accessed October 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10965":"<p><b>Title</b> Cardiac Glycosides / Diacerein</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diacerein may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for development of any cardiac glycoside-associated arrhythmias with concurrent use of diacerein.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> The diacerein labeling states that concurrent use with cardiac glycosides may increase the risk for arrhythmia development.<sup>1</sup> Specific data regarding this labeled interaction are not available.<br><br>The specific mechanism for this potential interaction is uncertain, but this may be related to a possible association between diacerein and electrolyte disturbances.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diacerein [prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802489. Accessed October 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10966":"<p><b>Title</b> CycloSPORINE (Systemic) / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cyclosporine if clarithromycin is initiated/dose increased, or decreased concentrations/effects if clarithromycin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Several case reports describe 1.5- to 7.5-fold increases in serum cyclosporine concentrations that occur within as few as 3 days of starting clarithromycin therapy.<sup>1,2,3,4,5,6</sup> Mean cyclosporine dose requirements were an average of 42% lower with one month of concurrent clarithromycin in a prospective study of 9 lung transplant recipients.<sup>7</sup> Cyclosporine prescribing information mentions that clarithromycin has been reported to increase concentrations but provides no additional information about the potential interaction.<sup>8</sup><br><br>The mechanism of this apparent interaction is likely related to the ability of clarithromycin to inhibit the CYP3A-mediated metabolism and/or the p-glycoprotein-mediated efflux of cyclosporine, resulting in increased cyclosporine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. <i>J Heart Lung Transplant</i>. 1994;13(2):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8031821\">[PubMed 8031821]</a></p>\n<p>2. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. <i>Transplantation</i>. 1994;58(6):725-727. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7940695\">[PubMed 7940695]</a></p>\n<p>3. Treille S, Quoidbach A, Demol H, Vereerstraeten P, Abramowicz D. Kidney graft dysfunction after drug interaction between clarithromycin and cyclosporin. <i>Nephrol Dial Transplant</i>. 1996;11(6):1192-1193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8672003\">[PubMed 8672003]</a></p>\n<p>4. Spicer ST, Liddle C, Chapman JR, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. <i>Br J Clin Pharmacol</i>. 1997;43(2):194-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9131953\">[PubMed 9131953]</a></p>\n<p>5. Sadaba B, Lopez de Ocariz A, Azanza JR, Quiroga J, Cienfuegos JA. Concurrent clarithromycin and cyclosporin A treatment. <i>J Antimicrob Chemother</i>. 1998;42(3):393-395. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9786481\">[PubMed 9786481]</a></p>\n<p>6. Sketris IS, Wright MR, West ML. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. <i>Pharmacotherapy</i>. 1996;16(2):301-305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8820476\">[PubMed 8820476]</a></p>\n<p>7. Knower MT, Labella-Walker K, McFadden PM, Kantrow SP, Valentine VG. Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. <i>South Med J</i>. 2000;93(11):1087-1092. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11095559\">[PubMed 11095559]</a></p>\n<p>8. Gengraf (cyclosporine) [prescribing information]. Chicago, IL: AbbVie Inc. (US); June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10967":"<p><b>Title</b> CycloSPORINE (Systemic) / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cyclosporine if erythromycin is initiated/dose increased, and decreased concentrations/effects if erythromycin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> A 2.1- and 2.2-fold average increase in cyclosporine AUC was reported with coadministration of erythromycin in two small studies of 6 renal transplant recipients and 10 healthy volunteers, respectively.<sup>1,2</sup> Multiple case reports have shown increases in cyclosporine AUC, minimum serum concentration, and whole blood concentrations, often associated with toxicities such as decreased renal function and confusion. Erythromycin and cyclosporine package inserts recommend close monitoring of serum concentration and dose adjustment of cyclosporine during concurrent use.<sup>3,4</sup><br><br>The mechanism of this apparent interaction is likely related to the ability of erythromycin to inhibit the CYP3A4-mediated metabolism and/or the p-glycoprotein-mediated efflux of cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. <i>Br J Clin Pharmacol</i>. 1989;27(4):475-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2655690\">[PubMed 2655690]</a></p>\n<p>2. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR. Cyclosporin-erythromycin interaction in normal subjects. <i>Br J Clin Pharmacol</i>. 1987;23(6):776-778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3606938\">[PubMed 3606938]</a></p>\n<p>3. Eryc (erythromycin) [prescribing information]. Parsippany, NJ: Warner Chilcott (US), LLC; June 2008.</p>\n<p>4. Gengraf (cyclosporine) [prescribing information]. Chicago, IL: AbbVie Inc. (US); June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10968":"<p><b>Title</b> CycloSPORINE (Systemic) / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cyclosporine if telithromycin is initiated/dose increased, or decreased concentrations/effects if telithromycin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> While no specific data exists for an interaction between telithromycin and cyclosporine, other macrolide antibiotics (erythromycin, clarithromycin, and azithromycin) have been reported to increase cyclosporine concentrations and to reduce cyclosporine dose requirements.<sup>1</sup> It is likely that telithromycin will also have an effect on cyclosporine concentration, warranting close monitoring of cyclosporine concentrations during concomitant therapy. <br><br>The mechanism of this apparent interaction is likely related to the ability of telithromycin to inhibit the CYP3A-mediated metabolism and/or the p-glycoprotein-mediated efflux of cyclosporine, resulting in increased cyclosporine concentrations. The telithromycin package insert states that telithromycin is a strong CYP3A4 inhibitor, and that drugs metabolized by CYP3A4, such as cyclosporine, should be used with caution.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: March 2015.</p>\n<p>2. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC: December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10969":"<p><b>Title</b> CycloSPORINE (Systemic) / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Azithromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cyclosporine if azithromycin is initiated/dose increased, or decreased effects if azithromycin is discontinued/dose decreased. Although azithromycin is likely a safer choice than other macrolides, monitoring serum cyclosporine concentrations during azithromycin therapy may be warranted.</p> \n<p><b>Discussion</b> Two case reports describe 2.2- and 5.5-fold increases in serum cyclosporine concentrations during concomitant azithromycin therapy.<sup>1,2</sup> However, two clinical studies report no significant change in cyclosporine concentrations with concurrent azithromycin. There was no significant change in cyclosporine concentration or renal function among 6 renal transplant recipients 7 days after initiation of a 3-day course of azithromycin in one study,<sup>3</sup> and a subsequent study using a 3-day azithromycin regimen in cyclosporine-stable patients also demonstrated no significant changes in the pharmacokinetics of cyclosporine.<sup>4</sup> Cyclosporine prescribing information does mention that azithromycin has been reported to increase concentrations but provides no additional information about the potential interaction.<sup>5</sup><br><br>The reason for any possible change in cyclosporine concentrations in response to azithromycin administration is unclear. Unlike the other macrolide antibiotics, azithromycin is not suspected to inhibit CYP3A4.<sup>3</sup> It has been proposed that azithromycin may interfere with the biliary excretion of cyclosporine, and azithromycin does appear to be a clinically relevant inhibitor of p-glycoprotein, an efflux transporter that is thought to transport cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Page RL 2nd, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. <i>Pharmacotherapy</i>. 2001;21(11):1436-1443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11714218\">[PubMed 11714218]</a></p>\n<p>2. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. <i>Nephron</i>. 1995;70(1):130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7617103\">[PubMed 7617103]</a></p>\n<p>3. Gomez E, Sanchez JE, Aguado S, Alvarez Grande J. Interaction between azithromycin and cyclosporin? <i>Nephron</i>. 1996;73(4):724. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8856287\">[PubMed 8856287]</a></p>\n<p>4. Bachmann K, Jauregui L, Chandra R, Thakker K. Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. <i>Pharmacol Res</i>. 2003;47(6):549-554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12742010\">[PubMed 12742010]</a></p>\n<p>5. Gengraf (cyclosporine) [prescribing information]. Chicago, IL: AbbVie Inc. (US); June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10970":"<p><b>Title</b> Heroin / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Heroin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of heroin (aka diactylmorphine) together with or within 2 weeks of discontinuing an MAO inhibitor should be avoided. This combination is specifically contraindicated in the labeling for some heroin products.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The labeling for several heroin (aka diactylmorphine) products state that concurrent use with an MAO inhibitor or within 2 weeks of discontinuing an MAO inhibitor should be avoided, and the combination is specifically contraindicated in some labeling.<sup>1,2,3</sup> Specific data concerning this combination is not provided.<br><br>The mechanism of this potential interaction is unclear. Whether the warning is primarily related to the potential for each agent to independently alter CNS activity, or whether elements relate to concerns over a potential for excessive serotonin stimulation is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diamorphine (diacetylmorphine) [summary of product characteristics]. Barnstaple, Devon, United Kingdom: Actavis UK Ltd.; February 2016.</p>\n<p>2. Diamorphine (diacetylmorphine) [summary of product characteristics]. Romford, Essex, United Kingdom: Martindale Pharmaceuticals Ltd UK; January 1998.</p>\n<p>3. Diamorphine (diacetylmorphine) [summary of product characteristics]. Camberley, Surrey, United Kingdom; Sandoz UK Ltd.; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10971":"<p><b>Title</b> Heroin / Quinolones</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinolones may enhance the adverse/toxic effect of Heroin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of CNS-related toxicities with concurrent use of heroin (aka diacetylmorphine) and quinolone antibiotics.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> Labeling for injectable heroin (aka diacetylmorphine) mentions a potential increased risk of toxicity with quinolone antibiotics.<sup>1</sup> Although the labeling doesn’t elaborate on the specific toxicity of concern, there is mention of possible CNS adverse events including hallucinations, toxic psychoses, and increased intracranial pressure,<sup>1,2,3</sup> and quinolones received a black box warning for similar CNS effects,<sup>4,5</sup> suggesting this as the possible reason for the labeled warning. There are no published data concerning this specific interaction, but other opioids have linked morphine, hydromorphone, and meperidine with seizures and other neurotoxicities, likely due to accumulation of toxic metabolites. Since diacetylmorphine is quickly metabolized to morphine, it is plausible that similar neurotoxicities can occur, and may be additive when combined with quinolone antibiotics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diamorphine (diacetylmorphine) [summary of product characteristics]. Barnstaple, Devon, United Kingdom: Actavis UK Ltd.; February 2016.</p>\n<p>2. Diamorphine (diacetylmorphine) [summary of product characteristics]. Romford, Essex, United Kingdom: Martindale Pharmaceuticals Ltd UK; January 1998.</p>\n<p>3. Diamorphine (diacetylmorphine) [summary of product characteristics]. Camberley, Surrey, United Kingdom; Sandoz UK Ltd.; September 2014.</p>\n<p>4. Cipro (ciprofloxacin) [prescribing information]. Leverkusen, Germany: Bayer HealthCare Pharmaceuticals Inc.; July 2016.</p>\n<p>5. Levaquin (levofloxacin) [prescribing information]. Raritan, NJ: Janssen Pharmaceuticals, Inc.; August 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10972":"<p><b>Title</b> Mexiletine / Heroin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heroin may decrease the absorption of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of decreased mexiletine effects.</p> \n<p><b>Discussion</b> Labeling for at least one injectable heroin (aka diacetylmorphine) product states that the absorption of mexiletine may be decreased or delayed with concurrent use of heroin.<sup>1</sup> Specific data concerning this potential interaction is not provided.<br><br>The specific mechanism for the interaction is uncertain, but opioids like heroin have been associated with diminished gastric emptying, possibly accounting for concerns of delayed or diminished absorption of orally administered mexiletine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diamorphine (diacetylmorphine) [summary of product characteristics]. Romford, Essex, United Kingdom: Martindale Pharmaceuticals Ltd UK; January 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10981":"<p><b>Title</b> Clopidogrel / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may diminish the therapeutic effect of Clopidogrel. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a retrospective study of the Taiwan National Health Insurance Database, 1,751 patients were admitted to the hospital with their first acute myocardial infarction (AMI) and discharged on clopidogrel therapy.<sup>1</sup> Within 90 days of the index hospital admission, 98 patients were readmitted with another AMI or reinfarction. Patients taking clopidogrel plus a proton pump inhibitor (PPI) had a higher risk for readmission compared with patients taking no PPI (odds ratio [OR], 1.62; 95% confidence interval [CI], 1.01 to 2.59), and a similar increased readmission risk was seen for patients taking clopidogrel plus cimetidine (OR, 1.97; 95% CI, 1.06 to 3.69).<sup>1</sup><br><br>While a statistically significant effect was seen with cimetidine coadministration, the small number of readmission events combined with the lack of adjustment for any other confounding variables (eg, age, comorbidities, family history) make the clinical significance of these results uncertain. <br><br>The mechanism of this potential interaction is unknown, but cimetidine is a weak CYP2C19 inhibitor and may inhibit the formation of the active clopidogrel metabolite.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. <i>Am J Gastroenterol</i>. 2009;104(12):3116-3117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19956146\">[PubMed 19956146]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10982":"<p><b>Title</b> Teneligliptin / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Teneligliptin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased teneligliptin effects/toxicities (ie, hypoglycemia, liver dysfunction, myalgias) if combined with ketoconazole.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy volunteers, ketoconazole (400 mg daily x 6 days) increased the teneligliptin (20 mg single dose) AUC and maximum serum concentration 49% and 37%, respectively.<sup>1</sup><br><br>The suspected mechanism of this interaction is ketoconazole inhibition of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in teneligliptin metabolism and distribution.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nakamaru Y, Hayashi Y, Sekine M, et al. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. <i>Clin Ther</i>. 2014;36(5):760-769. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24726088\">[PubMed 24726088]</a></p>\n<p>2. Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. <i>Xenobiotica</i>. 2014;44(3):242-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23855261\">[PubMed 23855261]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10983":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Teneligliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teneligliptin may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased QTc interval prolongation if teneligliptin is combined with high risk QTc-prolonging agents.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to a strict QT/QTc evaluation study and clinical studies for type 2 diabetes conducted in Japan and other countries, no adverse events related to QT prolongation were detected with up to 40 mg daily of teneligliptin.<sup>1</sup> However, one study evaluated the use of high-dose teneligliptin (160 mg daily x 4 days) and found that the placebo corrected mean QTc interval increased 9.3 milliseconds.<sup>1,2</sup><br><br>Teneligliptin product labeling states that the use of teneligliptin should be avoided in patients with long QT syndrome, and teneligliptin should be used cautiously in patients taking high risk QTc-prolonging agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. <i>Diabetes Metab Syndr Obes</i>. 2013;6:187-195. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23671395\">[PubMed 23671395]</a></p>\n<p>2. Teneligliptin [Korean prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201402038. Accessed August 8, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10984":"<p><b>Title</b> NIFEdipine / Nafcillin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nafcillin may decrease the serum concentration of NIFEdipine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternative antibiotic therapy in patients receiving nifedipine. Monitor for decreased therapeutic effects of nifedipine if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 healthy volunteers, the AUC of nifedipine (10 mg single oral dose) was decreased by 63%, and the clearance increased by 145%, when administered following a 5-day course of nafcillin (500 mg orally 4 times daily).<sup>1</sup><br><br>Nafcillin is a moderate inducer of CYP3A4 and nifedipine is a major substrate of this same isoenzyme.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC. Evidence of an interaction between nifedipine and nafcillin in humans. <i>Br J Clin Pharmacol</i>. 2003;55(6):588-590. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814453\">[PubMed 12814453]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10985":"<p><b>Title</b> Vitamin K Antagonists / Menadiol Diphosphate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Menadiol Diphosphate may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects (prothrombin time (PT)/ international normalized ratio (INR)) of vitamin K antagonists if menadiol, which is a water-soluble vitamin K analog, is initiated/dose increased, or increased effects (PT/INR) if menadiol is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The labeling for menadiol diphosphate, which is a water-soluble vitamin K analog, states that concurrent use with a vitamin K analog may result in a diminished anticoagulant effect.<sup>1</sup><br><br>Specific data with menadiol are not available, but several case reports of vitamin K antagonist “resistance” in patients consuming large daily quantities of vitamin K-rich foods<sup>2,3,4,5,6</sup> or enteral supplements<sup>7,8,9,10,11,12,13,14</sup> have been published. Vitamin K antagonists interfere with the ability of the body to effectively use vitamin K in the production of certain clotting factors (II, VII, IX, X). This interference can be overcome by administering adequate quantities of exogenous vitamin K.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Menadiol diphosphate [summary of product characteristics]. Chippenham, Wiltshire, United Kingdom: Alliance Pharmaceuticals Ltd; January 2015.</p>\n<p>2. Kempin SJ. Warfarin resistance caused by broccoli. <i>N Engl J Med</i>. 1983;308(20):1229-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6843604\">[PubMed 6843604]</a></p>\n<p>3. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. <i>Acta Med Scand</i>. 1986;220(4):347-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3541503\">[PubMed 3541503]</a></p>\n<p>4. Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening complication after dietary modification. <i>Postgrad Med J</i>. 1990;66(780):855-857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2099431\">[PubMed 2099431]</a></p>\n<p>5. Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussels sprouts on warfarin pharmacokinetics. <i>Eur J Clin Pharmacol</i>. 1988;34(5):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3203715\">[PubMed 3203715]</a></p>\n<p>6. Kalra PA, Cooklin M, Wood G, O'Shea GM, Holmes AM. Dietary modification as cause of anticoagulation instability. <i>Lancet</i>. 1988;2(8614):803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2901653\">[PubMed 2901653]</a></p>\n<p>7. O'Reilly RA, Rytand DA. “Resistance” to warfarin due to unrecognized vitamin K supplementation. <i>N Engl J Med</i>. 1980;303(3):160-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7383081\">[PubMed 7383081]</a></p>\n<p>8. Westfall LK. An unrecognized cause of warfarin resistance. <i>Drug Intell Clin Pharm</i>. 1981;15(2):131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7274023\">[PubMed 7274023]</a></p>\n<p>9. Zallman JA, Lee DP, Jeffrey PL. Liquid nutrition as a cause of warfarin resistance. <i>Am J Hosp Pharm</i>. 1981;38(8):1174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7270565\">[PubMed 7270565]</a></p>\n<p>10. Watson AJ, Pegg M, Green JR. Enteral feeds may antagonise warfarin. <i>Br Med J (Clin Res Ed)</i>. 1984;288(6416):557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6421377\">[PubMed 6421377]</a></p>\n<p>11. Lader E, Yang L, Clarke A. Warfarin dosage and vitamin K in Osmolite. <i>Ann Intern Med</i>. 1980;93(2):373-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7406391\">[PubMed 7406391]</a></p>\n<p>12. Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. <i>Clin Pharm</i>. 1982;1(3):274-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6821036\">[PubMed 6821036]</a></p>\n<p>13. Lee M, Schwartz RN, Sharifi R. Warfarin resistance and vitamin K. <i>Ann Intern Med</i>. 1981;94(1):140-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7447217\">[PubMed 7447217]</a></p>\n<p>14. Petretich DA. Reversal of osmolite-warfarin interaction by changing warfarin administration time. <i>Clin Pharm</i>. 1990;9(2):93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2106407\">[PubMed 2106407]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10986":"<p><b>Title</b> CarBAMazepine / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine serum concentrations and toxicities if combined with fluvoxamine.</p> \n<p><b>Discussion</b> A case report describes a female patient taking carbamazepine (600 mg daily for 4 years) who experienced an approximately 2.2-fold increase in carbamazepine plasma trough concentration and adverse events (tremor, irritability, dizziness, and fatigue) 1 week after initiation of fluvoxamine (100 mg daily).<sup>1</sup> Another case report describes similar increases in carbamazepine plasma concentrations and adverse events (nausea and vomiting) for 3 patients taking carbamazepine (600 mg to 1000 mg per day) after initiation of fluvoxamine (50 mg to 200 mg per day).<sup>2</sup> A third case report describes a 1.7-fold increase in carbamazepine plasma level and adverse event (fatigue) for a patient taking carbamazepine (600 mg to 800 mg per day) after initiation of fluvoxamine (600 mg daily).<sup>3</sup> <br><br>In contrast, a pharmacokinetic study of 7 epileptic patients stabilized on carbamazepine (800 mg to 1,600 mg per day) reported no significant adverse events or changes in the steady-state plasma levels of carbamazepine when coadministered with fluvoxamine (100 mg daily for 3 weeks).<sup>4</sup> Prescribing information for both fluvoxamine and carbamazepine states that increased carbamazepine plasma levels and toxicities have been seen when these agents were coadministered.<sup>5,6</sup> <br><br>The mechanism of this interaction has not been fully investigated, but fluvoxamine-mediated inhibition of CYP3A4, an enzyme involved in carbamazepine metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. <i>Br J Clin Pharmacol</i>. 1993:36(6):615-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12959283\">[PubMed 12959283]</a></p>\n<p>2. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. <i>Acta Psychiatr Scand</i>. 1991:84(6):583-584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1792934\">[PubMed 1792934]</a></p>\n<p>3. Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? <i>Therapie</i>. 1992:47(2):165. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1412145\">[PubMed 1412145]</a></p>\n<p>4. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. <i>Ther Drug Monit</i>. 1993:15(3):247-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8333006\">[PubMed 8333006]</a></p>\n<p>5. Luvox (fluvoxamine maleate) [prescribing information] Baudette, MN: ANI Pharmaceuticals Inc; January 2017. </p>\n<p>6. Tegretol XR (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10987":"<p><b>Title</b> Citalopram / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Citalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of citalopram if combined with carbamazepine.</p> \n<p><b>Discussion</b> In a study of 6 patients with major depressive disorder, the addition of carbamazepine (200 mg to 400 mg daily x 14 days) to citalopram (40 mg to 60 mg daily) decreased S-citalopram and R-citalopram plasma concentrations 27% and 31%, respectively.<sup>1</sup> Another report describes 2 patients who experienced subtherapeutic citalopram concentrations and a lack of citalopram efficacy in the presence of carbamazepine (400 mg to 800 mg daily).<sup>2</sup> Once carbamazepine was discontinued and switched to oxcarbazepine (a significantly weaker CYP3A4 inducer), citalopram levels increased 241% to 700%.<sup>2</sup> Additionally, in a pharmacokinetic study of 12 healthy volunteers, citalopram (40 mg daily x 14 days) had no effect on the pharmacokinetics of carbamazepine (400 mg daily x 35 days).<sup>3</sup> <br><br>Citalopram and carbamazepine prescribing information state that citalopram clearance may be increased, resulting in decreased citalopram serum levels, with carbamazepine coadministration.<sup>4,5</sup><br><br>The mechanism of this interaction is likely carbamazepine induction of CYP3A4, an enzyme at least partially responsible for citalopram metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>Eur Neuropsychopharmacol</i>. 2002:12(3):255-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12007677\">[PubMed 12007677]</a></p>\n<p>2. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. <i>Pharmacopscyhiatry</i>. 1996:29(4):156-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8858715\">[PubMed 8858715]</a></p>\n<p>3. Moller SE, Larsen F, Khan AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. <i>J Clin Psychopharmacol</i>. 2001:21(5):493-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11593075\">[PubMed 11593075]</a></p>\n<p>4. Celexa (citalopram hydrobromide) [prescribing information] St. Louis, MO: Forest Pharmaceutics Inc; August 2011. </p>\n<p>5. Tegretol XR (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10988":"<p><b>Title</b> Propranolol / Chlormethiazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Chlormethiazole may enhance the bradycardic effect of Propranolol. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to the chlormethiazole (aka clomethiazole) labeling, substantial bradycardia in an individual patient has been reported associated with the combination of chlormethiazole and propranolol.<sup>1</sup> The degree to which this is the result of an interaction between these drugs is uncertain. Similarly, the specific mechanism for any such interaction is unknown, but the chlormethiazole labeling suggests increased propranolol bioavailability may be responsible.<sup>1</sup> Chlormethiazole has been described as a possible CYP2E1 inhibitor, but there is no published evidence that CYP2E1 has a significant role in propranolol metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10989":"<p><b>Title</b> Chlormethiazole / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Chlormethiazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased chlormethiazole effects or toxicities when used together with cimetidine.</p> \n<p><b>Discussion</b> The chlormethiazole (aka clomethiazole) clearance was an average of 31% lower with concurrent administration of cimetidine (1 g/day for 7 days), and the chlormethiazole half-life was an average of 60% longer.<sup>1</sup> The clinical significance of this reported interaction is uncertain.<br><br>The mechanism of this apparent interaction is cimetidine inhibition of chlormethiazole metabolism, possibly leading to increased chlormethiazole serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. <i>Eur J Clin Pharmacol</i>. 1981;21(1):83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7333351\">[PubMed 7333351]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10990":"<p><b>Title</b> Chlormethiazole / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Chlormethiazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced chlormethiazole effects if used together with carbamazepine.</p> \n<p><b>Discussion</b> According to the chlormethiazole (aka clomethiazole) labeling, the chlormethiazole clearance was 30% higher with concurrent carbamazepine, and serum chlormethiazole concentrations were proportionately lower.<sup>1</sup> It is noted that this was observed with intravenous chlormethiazole, so it is uncertain whether the interaction will be similar with orally-administered chlormethiazole. The clinical significance of this reported interaction is uncertain.<br><br>The mechanism of this apparent interaction is carbamazepine induction of chlormethiazole metabolism, leading to decreased chlormethiazole serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10991":"<p><b>Title</b> CNS Depressants / Chlormethiazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chlormethiazole may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the chlormethiazole (aka clomethiazole) labeling, fatal cardiorespiratory collapse has been reported with concurrent use of other CNS depressants.<sup>1</sup> An appropriately reduced dose is recommended with any such concurrent use.<br><br>The likely mechanism for any such interaction is additive or synergistic CNS depression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10992":"<p><b>Title</b> Chlormethiazole / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: This combination should specifically be avoided in alcoholics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Chlormethiazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of excessive depressant effects with use of chlormethiazole together with alcohol, and caution patients about the potential for serious CNS depression with any concurrent used. Chlormethiazole should not be used in alcoholics who continue to consume alcohol.</p> \n<p><b>Discussion</b> According to the chlormethiazole (aka clomethiazole) labeling, fatal respiratory depression has been reported with concurrent use of alcohol, including even short-term use.<sup>1</sup> The risks of this combination have been publicized, but there is some question whether the risks reflect those of any combined CNS depressants or some uniquely increased risk with chlormethiazole.<sup>2</sup> Although it does seem that cirrhosis and possibly other effects of chronic alcoholism may impair chlormethiazole metabolism,<sup>1</sup> acute alcohol ingestion appears to have no significant effect on chlormethiazole disposition.<sup>3</sup><br><br>The mechanism for any such interaction is uncertain but like involves additive or synergistic CNS depression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.</p>\n<p>2. McInnes GT. Chlormethiazole and alcohol: a lethal cocktail. <i>Br Med J (Clin Res Ed)</i>. 1987;294(6572):592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3103815\">[PubMed 3103815]</a></p>\n<p>3. Bury RW, Desmond PV, Mashford ML, Westwood B, Shaw G, Breen KJ. The effect of ethanol administration on the disposition and elimination of chlormethiazole. <i>Eur J Clin Pharmacol</i>. 1983;24(3):383-385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6861852\">[PubMed 6861852]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10993":"<p><b>Title</b> CarBAMazepine / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FLUoxetine may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine serum concentrations and toxicities if combined with fluoxetine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy male volunteers, fluoxetine (20 mg daily x 7 days) increased the carbamazepine (400 mg daily x 3 weeks) AUC and half-life 27% and 25%, respectively, and decreased the carbamazepine clearance 23%.<sup>1</sup> Several case reports describe patients stabilized on carbamazepine therapy who experienced increased carbamazepine concentrations (11% to 63%),<sup>2,3</sup> carbamazepine toxicities (eg, nausea, vomiting, blurred vision, tremor, vertigo, parkinsonism),<sup>2,3</sup> and possible serotonin syndrome after the initiation of fluoxetine therapy.<sup>4</sup> <br><br>In contrast, a pharmacokinetic study of 8 epileptic patients stabilized on carbamazepine (800 mg to 1,600 mg per day) reported no significant changes in the steady-state plasma levels of carbamazepine after initiation of fluoxetine (20 mg daily x 3 weeks).<sup>5</sup> However, 2 patients did experience increased adverse events (nervousness and headache).<sup>5</sup> <br><br>The fluoxetine and carbamazepine prescribing information both state that increased carbamazepine plasma levels and toxicities have been seen when these agents are combined.<sup>6,7</sup> <br><br>The mechanism of this potential interaction is unknown, but fluoxetine-mediated competition for, or inhibition of, CYP3A4 may contribute, as CYP3A4 is primarily responsible for carbamazepine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. <i>Clin Pharmacol Ther</i>. 1991:50(1):10-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1855347\">[PubMed 1855347]</a></p>\n<p>2. Pearson HJ. Interaction of fluoxetine with carbamazepine. <i>J Clin Psychiatry</i>. 1990:51(3):126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2353956\">[PubMed 2353956]</a></p>\n<p>3. Gernaat HB, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine. <i>Am J Psychiatry</i>. 1991:148(11):1604-1605. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1928486\">[PubMed 1928486]</a></p>\n<p>4. Dursun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. <i>Lancet</i>. 1993:342(8868):442-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8101947\">[PubMed 8101947]</a></p>\n<p>5. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. <i>Ther Drug Monit</i>. 1993:15(3):247-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8333006\">[PubMed 8333006]</a></p>\n<p>6. Prozac (fluoxetine) [prescribing information] Indianapolis, IN: Eli Lilly and Co; October 2016. </p>\n<p>7. Tegretol XR (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10994":"<p><b>Title</b> Rupatadine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of strong CYP3A4 inhibitors together with rupatadine should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to rupatadine labeling, concurrent use with the strong CYP3A4 inhibitor ketoconazole was associated with a 10-fold increase in rupatadine concentrations.<sup>1,2,3</sup> Although there was no apparent increase in adverse reactions, the use of this combination should be avoided.<br><br>The mechanism for this interaction appears to be inhibition of the CYP3A4-mediated metabolism of rupatadine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rupatadine [UK summary of product characteristics]. Palau-solita i Plegamans, Spain: J. Uriach &amp; Cia., S.A.; August 2016.</p>\n<p>2. Rupafin (rupatadine) [Singapore prescribing information]. Alcobendas, Madrid, Spain: Italfarmaco, S.A.; October 2015.</p>\n<p>3. Rupafin (rupatadine) [Brazil prescribing information]. Sao Paulo, Brazil: Biosintetica Farmaceutica Ltda.; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10995":"<p><b>Title</b> Rupatadine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of moderate CYP3A4 inhibitors together with rupatadine should be considered with caution. If the combination is used, monitor patients closely for evidence of increased adverse reactions to rupatadine. Concurrent use of grapefruit juice, which is a moderate CYP3A4 inhibitor, should be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to rupatadine labeling, concurrent use with the moderate CYP3A4 inhibitor erythromycin was associated with a 2- to 3-fold increase in rupatadine concentrations.<sup>1,2,3</sup> Concurrent use with grapefruit juice, which is also a moderate CYP3A4 inhibitor, was associated with a 3.5-fold increase in rupatadine concentrations. There was no apparent increase in adverse reactions with these combinations. Rupatadine labeling recommends avoiding concurrent use of grapefruit juice<sup>1,2,3</sup> and caution with the use of other moderate CYP3A4 inhibitors.<sup>1,2</sup> Note that at least one label suggests that concurrent use of all CYP3A4 inhibitors should be avoided.<sup>3</sup><br><br>The mechanism for this interaction appears to be inhibition of the CYP3A4-mediated metabolism of rupatadine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rupatadine [UK summary of product characteristics]. Palau-solita i Plegamans, Spain: J. Uriach &amp; Cia., S.A.; August 2016.</p>\n<p>2. Rupafin (rupatadine) [Singapore prescribing information]. Alcobendas, Madrid, Spain: Italfarmaco, S.A.; October 2015.</p>\n<p>3. Rupafin (rupatadine) [Brazil prescribing information]. Sao Paulo, Brazil: Biosintetica Farmaceutica Ltda.; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10996":"<p><b>Title</b> Rupatadine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Rupatadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consumption of grapefruit juice together with rupatadine should be avoided.</p> \n<p><b>Discussion</b> According to rupatadine labeling, concurrent use with grapefruit juice was associated with a 3.5-fold increase in rupatadine concentrations.<sup>1,2,3</sup> Labeling states that this combination should be avoided.<br><br>The mechanism for this interaction appears to be inhibition of the CYP3A4-mediated metabolism of rupatadine, but inhibition of intestinal p-glycoprotein may also be partially involved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rupatadine [UK summary of product characteristics]. Palau-solita i Plegamans, Spain: J. Uriach &amp; Cia., S.A.; August 2016.</p>\n<p>2. Rupafin (rupatadine) [Singapore prescribing information]. Alcobendas, Madrid, Spain: Italfarmaco, S.A.; October 2015.</p>\n<p>3. Rupafin (rupatadine) [Brazil prescribing information]. Sao Paulo, Brazil: Biosintetica Farmaceutica Ltda.; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10997":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Rupatadine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rupatadine may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of muscle toxicities (including myalgias, increases in CPK, etc.) with use of this combination.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> According to rupatadine labeling, concurrent use with HMG CoA-reductase inhibitors (aka statins), should be undertaken with caution.<sup>1,2,3</sup> Increases in CPK have been reported with independent use of rupatadine, suggesting that an increase in the risk for muscle-related toxicities may occur with use of statins, which have also been independently associated with muscle toxicities.<br><br>The specific mechanism for this potential interaction is unknown but appears to be concerns over additive or synergistic muscle toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rupatadine [UK summary of product characteristics]. Palau-solita i Plegamans, Spain: J. Uriach &amp; Cia., S.A.; August 2016.</p>\n<p>2. Rupafin (rupatadine) [Singapore prescribing information]. Alcobendas, Madrid, Spain: Italfarmaco, S.A.; October 2015.</p>\n<p>3. Rupafin (rupatadine) [Brazil prescribing information]. Sao Paulo, Brazil: Biosintetica Farmaceutica Ltda.; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}